Linezolid to treat MDR-/XDR-tuberculosis: Available evidence and future scenarios

European Respiratory Journal

Volumn 45, Issue 1, 2015, Pages 25-29

  Sotgiu, Giovanni ^a   Pontali, Emanuele ^b   Migliori, Giovanni Battista ^c  

^a UNIVERSITY OF SASSARI   (Italy)

^b GALLIERA HOSPITAL   (Italy)

^c WORLD HEALTH ORGANIZATION   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; BEDAQUILINE; CAPREOMYCIN; COTRIMOXAZOLE; DELAMANID; KANAMYCIN; LINEZOLID; MEROPENEM; QUINOLONE DERIVATIVE; TUBERCULOSTATIC AGENT;

ANTIBIOTIC RESISTANCE; BACTERIAL STRAIN; BACTERIUM ISOLATE; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; EXTENSIVELY DRUG RESISTANT TUBERCULOSIS; GASTROINTESTINAL DISEASE; HEMATOLOGIC DISEASE; HUMAN; LOW DRUG DOSE; MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; NEUROLOGIC DISEASE; NONHUMAN; PREVALENCE; PUBLIC HEALTH PROBLEM; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; TREATMENT DURATION; WORLD HEALTH ORGANIZATION; COHORT ANALYSIS; COMMUNICABLE DISEASE CONTROL; EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS; PROCEDURES; TREATMENT OUTCOME; TUBERCULOSIS, MULTIDRUG-RESISTANT;

ANTITUBERCULAR AGENTS; COHORT STUDIES; COMMUNICABLE DISEASE CONTROL; DRUG RESISTANCE, BACTERIAL; EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS; HUMANS; LINEZOLID; TREATMENT OUTCOME; TUBERCULOSIS, MULTIDRUG-RESISTANT; WORLD HEALTH ORGANIZATION;

EID: 84920583395     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00145014     Document Type: Review

References (41)

1. World Health Organization. Global Tuberculosis Report 2013. Geneva, WHO, 2013.
2. Sotgiu G, Mauch V, Migliori GB, et al. Evidence-based, agreed-upon health priorities to remedy the tuberculosis patient's economic disaster. Eur Respir J 2014; 43: 1563-1566.
3. Voniatis C, Migliori GB, Voniatis M, et al. Tuberculosis elimination: dream or reality? The case of Cyprus. Eur Respir J 2014; 44: 543-546.
4. Sotgiu G, Migliori GB. Is tuberculosis elimination a reality? Lancet Infect Dis 2014; 14: 364-365.
5. Falzon D, Zellweger J-P, Migliori GB, et al. Drug-resistance and tuberculosis elimination in low-incidence countries. Eur Respir J 2014; 44: 1408-1411.
6. Zignol M, Dara M, Dean AS, et al. Drug-resistant tuberculosis in the WHO European Region: an analysis of surveillance data. Drug Resist Updat 2013; 16: 108-115.
7. Ulmasova DJ, Uzakova G, Tillyashayhov MN, et al. Multidrug-resistant tuberculosis in Uzbekistan: results of a nationwide survey, 2010 to 2011. Euro Surveill 2013; 18.
8. Skrahina A, Hurevich H, Zalutskaya A, et al. Alarming levels of drug-resistant tuberculosis in Belarus: results of a survey in Minsk. Eur Respir J 2012; 39: 1425-1431.
9. Falzon D, Jaramillo E, Wares F, et al. Universal access to care for multidrug-resistant tuberculosis: an analysis of surveillance data. Lancet Infect Dis 2013; 13: 690-697.
10. Ahuja SD, Ashkin D, Avendano M, et al. Multidrug resistant pulmonary tuberculosis treatment regimens and patient outcomes: an individual patient data meta-analysis of 9,153 patients. PLoS Med 2012; 9: e1001300.
11. Falzon D, Gandhi N, Migliori GB, et al. Resistance to fluoroquinolones and second-line injectable drugs: impact on multidrug-resistant TB outcomes. Eur Respir J 2013; 42: 156-168.
12. Migliori GB, Sotgiu G, Gandhi NR, et al. Drug resistance beyond extensively drug-resistant tuberculosis: individual patient data meta-analysis. Eur Respir J 2013; 42: 169-179.
13. Falzon D, Jaramillo E, Schünemann HJ, et al. WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update. Eur Respir J 2011; 38: 516-528.
14. Migliori GB, Sotgiu G, Lange C, et al. Extensively drug-resistant tuberculosis: back to the future. Eur Respir J 2010; 36: 475-477.
15. Hanson C, Sotgiu G, Loddenkemper R. Ensuring that the diagnosis of tuberculosis accelerates progress towards the Millennium Development Goals. Eur Respir J 2014; 44: 1-4.
16. Raviglione M, Marais B, Floyd K, et al. Scaling up interventions to achieve global tuberculosis control: progress and new developments. Lancet 2012; 379: 1902-1913.
17. Zumla AI, Gillespie SH, Hoelscher M, et al. New antituberculosis drugs, regimens, and adjunct therapies: needs, advances, and future prospects. Lancet Infect Dis 2014; 14: 327-340.
18. Kwon YS, Jeong BH, Koh WJ. Tuberculosis: clinical trials and new drug regimens. Curr Opin Pulm Med 2014; 20: 280-286.
19. Skripconoka V, Danilovits M, Pehme L, et al. Delamanid improves outcomes and reduces mortality in multidrug-resistant tuberculosis. Eur Respir J 2013; 41: 1393-1400.
20. Tiberi S, De Lorenzo S, Centis R, et al. Bedaquiline in MDR/XDR-TB cases: first experience on compassionate use. Eur Respir J 2014; 43: 289-292.
21. van Halsema C, Humphreys S, Bonington A. Extensively drug-resistant tuberculosis: early access to bedaquiline for a UK patient. Eur Respir J 2014; 43: 292-294.
22. Diacon AH, Donald PR, Pym A, et al. Randomized pilot trial of eight weeks of bedaquiline (TMC207) treatment for multidrug-resistant tuberculosis: long-term outcome, tolerability, and effect on emergence of drug resistance. Antimicrob Agents Chemother 2012; 56: 3271-3276.
23. Elzinga G, Raviglione MC, Maher D. Scale up: meeting targets in global tuberculosis control. Lancet 2004; 363: 814-819.
24. Raviglione MC, Lange C, Migliori GB. Preventing and managing antimicrobial resistance: imperative for chest physicians. Eur Respir J 2011; 37: 978-981.
25. Gospodarevskaya E, Tulloch O, Bunga C, et al. Patient costs during tuberculosis treatment in Bangladesh and Tanzania: the potential of shorter regimens. Int J Tuberc Lung Dis 2014; 18: 810-817.
26. Fofana MO, Knight GM, Gomez GB, et al. Population-level impact of shorter-course regimens for tuberculosis: a model-based analysis. PLoS One 2014; 9: e96389.
27. De Lorenzo S, Alffenaar JW, Sotgiu G, et al. Efficacy and safety of meropenem-clavulanate added to linezolid-containing regimens in the treatment of MDR-/XDR-TB. Eur Respir J 2013; 41: 1386-1392.
28. Alsaad N, van Altena R, Pranger AD, et al. Evaluation of co-trimoxazole in the treatment of multidrug-resistant tuberculosis. Eur Respir J 2013; 42: 504-512.
29. Migliori GB, Eker B, Richardson MD, et al. A retrospective TBNET assessment of linezolid safety, tolerability and efficacy in multidrug-resistant tuberculosis. Eur Respir J 2009; 34: 387-393.
30. Cox H, Ford N. Linezolid for the treatment of complicated drug-resistant tuberculosis: a systematic review and meta-analysis. Int J Tuberc Lung Dis 2012; 16: 447-454.
31. Sotgiu G, Centis R, D'Ambrosio L, et al. Efficacy, safety and tolerability of linezolid containing regimens in treating MDR-TB and XDR-TB: systematic review and meta-analysis. Eur Respir J 2012; 40: 1430-1442.
32. Lee M, Lee J, Carroll MW, et al. Linezolid for treatment of chronic extensively drug-resistant tuberculosis. N Engl J Med 2012; 367: 1508-1518.
33. Sotgiu G, Centis R, D'Ambrosio L, et al. Linezolid to treat extensively drug-resistant TB: retrospective data are confirmed by experimental evidence. Eur Respir J 2013; 42: 288-290.
34. Tang S, Yao L, Hao X, et al. Efficacy, safety and tolerability of linezolid for the treatment of XDR-TB: a study in China. Eur Respir J 2015; 45: 161-170.
35. Zhang L, Pang Y, Yu X, et al. Linezolid in the treatment of extensively drug-resistant tuberculosis. Infection 2014; 42: 705-711.
36. Xu HB, Jiang RH, Li L, et al. Linezolid in the treatment of MDR-TB: a retrospective clinical study. Int J Tuberc Lung Dis 2012; 16: 358-363.
37. Esposito S, D'Ambrosio L, Tadolini M, et al. ERS/WHO Tuberculosis Consilium assistance with extensively drug-resistant tuberculosis management in a child: case study of compassionate delamanid use. Eur Respir J 2014; 44: 811-815.
38. Srivastava S, Peloquin CA, Sotgiu G, et al. Therapeutic drug management: is it the future of multidrug-resistant tuberculosis treatment? Eur Respir J 2013; 42: 1449-1453.
39. Diel R, Vandeputte J, de Vries G, et al. Costs of tuberculosis disease in the European Union: a systematic analysis and cost calculation. Eur Respir J 2014; 43: 554-565.
40. Migliori GB, Lienhardt C, Weyer K, et al. Ensuring rational introduction and responsible use of new TB tools: outcome of an ERS multisector consultation. Eur Respir J 2014; 44: 1412-1417.
41. World Health Organization. The use of bedaquiline in the treatment of multidrug-resistant tuberculosis. Interim policy guidance. Geneva, WHO, 2013.